| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.943 | 0.003 | 0.972 | Aldehyde oxidase inhibitor | 0.898 0.003 DBMET02565 0.87 0.004 DBMET02566 0.972 0.002 DBMET02567 | DBMET02567 | |
| 0.684 | 0.005 | 0.714 | Anticonvulsant | 0.587 0.008 DBMET02565 0.714 0.005 DBMET02566 0.562 0.009 DBMET02567 | DBMET02566 | |
| 0.664 | 0.004 | 0.664 | Dopamine antagonist | 0.555 0.005 DBMET02565 0.624 0.004 DBMET02566 0.579 0.005 DBMET02567 | ||
| 0.654 | 0.005 | 0.654 | 5 Hydroxytryptamine antagonist | 0.626 0.005 DBMET02565 0.332 0.015 DBMET02566 0.415 0.01 DBMET02567 | ||
| 0.636 | 0.003 | 0.736 | Histamine H1 receptor antagonist | 0.437 0.004 DBMET02565 0.736 0.003 DBMET02566 0.434 0.004 DBMET02567 | DBMET02566 | |
| 0.633 | 0.004 | 0.64 | 5 Hydroxytryptamine 2C antagonist | 0.64 0.004 DBMET02565 0.277 0.01 DBMET02566 0.417 0.005 DBMET02567 | DBMET02565 | |
| 0.614 | 0.004 | 0.614 | 5 Hydroxytryptamine 2B antagonist | 0.594 0.004 DBMET02565 0.319 0.013 DBMET02566 0.497 0.005 DBMET02567 | ||
| 0.611 | 0.004 | 0.611 | 5 Hydroxytryptamine 2 antagonist | 0.601 0.004 DBMET02565 0.313 0.015 DBMET02566 0.464 0.007 DBMET02567 | ||
| 0.617 | 0.011 | 0.617 | Spasmolytic | 0.497 0.023 DBMET02565 0.43 0.034 DBMET02566 0.606 0.012 DBMET02567 | ||
| 0.631 | 0.032 | 0.766 | Caspase 9 stimulant | 0.729 0.02 DBMET02565 0.334 0.159 DBMET02566 0.766 0.016 DBMET02567 | DBMET02567 | |
| 0.602 | 0.004 | 0.602 | Dopamine D4 antagonist | 0.411 0.005 DBMET02565 0.234 0.01 DBMET02566 0.458 0.004 DBMET02567 | ||
| 0.592 | 0.003 | 0.696 | Dopamine D1 antagonist | 0.421 0.004 DBMET02565 0.291 0.006 DBMET02566 0.696 0.003 DBMET02567 | DBMET02567 | |
| 0.591 | 0.004 | 0.591 | Dopamine D2 antagonist | 0.5 0.005 DBMET02565 0.589 0.004 DBMET02566 0.504 0.005 DBMET02567 | ||
| 0.566 | 0.004 | 0.566 | 5 Hydroxytryptamine 2A antagonist | 0.548 0.004 DBMET02565 0.283 0.012 DBMET02566 0.402 0.007 DBMET02567 | ||
| 0.547 | 0.005 | 0.591 | Alpha adrenoreceptor antagonist | 0.591 0.005 DBMET02565 0.224 0.024 DBMET02566 0.429 0.008 DBMET02567 | DBMET02565 | |
| 0.544 | 0.004 | 0.581 | Alpha 2b adrenoreceptor antagonist | 0.581 0.004 DBMET02565 0.283 0.01 DBMET02566 0.449 0.004 DBMET02567 | DBMET02565 | |
| 0.537 | 0.019 | 0.555 | Histamine release inhibitor | 0.482 0.036 DBMET02565 0.435 0.058 DBMET02566 0.555 0.015 DBMET02567 | DBMET02567 | |
| 0.492 | 0.005 | 0.587 | Antihistaminic | 0.385 0.006 DBMET02565 0.587 0.004 DBMET02566 0.225 0.017 DBMET02567 | DBMET02566 | |
| 0.48 | 0.005 | 0.54 | Histamine antagonist | 0.374 0.007 DBMET02565 0.54 0.004 DBMET02566 0.206 0.018 DBMET02567 | DBMET02566 | |
| 0.481 | 0.008 | 0.523 | Cyclic AMP phosphodiesterase inhibitor | 0.47 0.009 DBMET02565 0.266 0.056 DBMET02566 0.523 0.005 DBMET02567 | DBMET02567 | |
| 0.473 | 0.004 | 0.473 | Nav1.3 sodium channel blocker | 0.389 0.005 DBMET02565 0.227 0.018 DBMET02566 0.308 0.008 DBMET02567 | ||
| 0.462 | 0.004 | 0.462 | 5 Hydroxytryptamine 1F antagonist | 0.4 0.005 DBMET02565 0.208 0.01 DBMET02566 0.282 0.006 DBMET02567 | ||
| 0.449 | 0.005 | 0.496 | Alpha 1 adrenoreceptor antagonist | 0.496 0.005 DBMET02565 0.187 0.023 DBMET02566 0.327 0.009 DBMET02567 | DBMET02565 | |
| 0.442 | 0.005 | 0.447 | 5 Hydroxytryptamine 7 antagonist | 0.447 0.005 DBMET02565 0.242 0.009 DBMET02566 0.228 0.01 DBMET02567 | DBMET02565 | |
| 0.44 | 0.004 | 0.44 | Dopamine D3 antagonist | 0.338 0.005 DBMET02565 0.233 0.009 DBMET02566 0.325 0.005 DBMET02567 | ||
| 0.439 | 0.005 | 0.439 | 5 Hydroxytryptamine 1A antagonist | 0.434 0.005 DBMET02565 0.147 0.02 DBMET02566 0.303 0.009 DBMET02567 | ||
| 0.434 | 0.005 | 0.434 | 5 Hydroxytryptamine 1 antagonist | 0.398 0.006 DBMET02565 0.145 0.025 DBMET02566 0.28 0.011 DBMET02567 | ||
| 0.433 | 0.004 | 0.49 | Alpha 2a adrenoreceptor antagonist | 0.49 0.004 DBMET02565 0.178 0.017 DBMET02566 0.393 0.005 DBMET02567 | DBMET02565 | |
| 0.43 | 0.005 | 0.442 | Alpha 1b adrenoreceptor antagonist | 0.442 0.004 DBMET02565 0.198 0.015 DBMET02566 0.338 0.006 DBMET02567 | DBMET02565 | |
| 0.409 | 0.005 | 0.55 | NADPH oxidase inhibitor | 0.387 0.005 DBMET02565 0.126 0.075 DBMET02566 0.55 0.004 DBMET02567 | DBMET02567 | |
| 0.408 | 0.004 | 0.413 | Alpha 2c adrenoreceptor antagonist | 0.413 0.004 DBMET02565 0.193 0.02 DBMET02566 0.328 0.005 DBMET02567 | DBMET02565 | |
| 0.425 | 0.024 | 0.425 | HERG channel blocker | 0.395 0.029 DBMET02565 0.363 0.034 DBMET02566 0.198 0.092 DBMET02567 | ||
| 0.402 | 0.007 | 0.402 | Nav1.2 sodium channel blocker | 0.394 0.007 DBMET02565 0.186 0.04 DBMET02566 0.342 0.011 DBMET02567 | ||
| 0.411 | 0.02 | 0.411 | Sigma receptor agonist | 0.292 0.04 DBMET02565 0.34 0.032 DBMET02566 0.355 0.029 DBMET02567 | ||
| 0.408 | 0.021 | 0.411 | Psychostimulant | 0.411 0.021 DBMET02565 0.405 0.022 DBMET02566 0.333 0.035 DBMET02567 | DBMET02565 | |
| 0.385 | 0.009 | 0.463 | Antiadrenergic | 0.463 0.006 DBMET02565 0.189 0.026 DBMET02566 0.287 0.014 DBMET02567 | DBMET02565 | |
| 0.382 | 0.006 | 0.382 | Acetylcholine M1 receptor antagonist | 0.306 0.013 DBMET02565 0.267 0.021 DBMET02566 0.33 0.01 DBMET02567 | ||
| 0.393 | 0.023 | 0.396 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.396 0.022 DBMET02565 0.283 0.077 DBMET02566 0.338 0.041 DBMET02567 | DBMET02565 | |
| 0.374 | 0.006 | 0.374 | 5 Hydroxytryptamine 1E antagonist | 0.341 0.012 DBMET02565 0.304 0.027 DBMET02566 0.346 0.011 DBMET02567 | ||
| 0.376 | 0.009 | 0.455 | Adrenaline antagonist | 0.455 0.006 DBMET02565 0.184 0.027 DBMET02566 0.279 0.015 DBMET02567 | DBMET02565 | |
| 0.373 | 0.006 | 0.442 | Alpha 1a adrenoreceptor antagonist | 0.442 0.005 DBMET02565 0.133 0.026 DBMET02566 0.261 0.011 DBMET02567 | DBMET02565 | |
| 0.4 | 0.035 | 0.413 | Vasodilator, coronary | 0.398 0.036 DBMET02565 0.272 0.113 DBMET02566 0.413 0.031 DBMET02567 | DBMET02567 | |
| 0.366 | 0.004 | 0.405 | Alpha 1d adrenoreceptor antagonist | 0.405 0.004 DBMET02565 0.156 0.014 DBMET02566 0.251 0.007 DBMET02567 | DBMET02565 | |
| 0.375 | 0.031 | 0.375 | Potassium channel (Voltage-sensitive) blocker | 0.346 0.037 DBMET02565 0.312 0.046 DBMET02566 0.189 0.103 DBMET02567 | ||
| 0.395 | 0.064 | 0.395 | GABA C receptor rho-3 antagonist | 0.339 0.092 DBMET02565 0.319 0.103 DBMET02566 0.39 0.066 DBMET02567 | ||
| 0.319 | 0.004 | 0.319 | Dopamine uptake inhibitor | 0.233 0.005 DBMET02565 0.189 0.007 DBMET02566 0.203 0.006 DBMET02567 | ||
| 0.33 | 0.015 | 0.33 | Cytidine deaminase inhibitor | 0.23 0.035 DBMET02565 0.228 0.036 DBMET02566 0.225 0.037 DBMET02567 | ||
| 0.314 | 0.004 | 0.314 | Acetylcholine M4 receptor antagonist | 0.224 0.005 DBMET02565 0.167 0.008 DBMET02566 0.134 0.014 DBMET02567 | ||
| 0.316 | 0.007 | 0.37 | Alpha 2 adrenoreceptor antagonist | 0.37 0.005 DBMET02565 0.123 0.035 DBMET02566 0.25 0.011 DBMET02567 | DBMET02565 | |
| 0.318 | 0.011 | 0.318 | Anesthetic local | 0.216 0.028 DBMET02565 0.137 0.055 DBMET02566 0.246 0.021 DBMET02567 | ||
| 0.303 | 0.005 | 0.303 | 5 Hydroxytryptamine 1B antagonist | 0.271 0.005 DBMET02565 0.109 0.02 DBMET02566 0.152 0.012 DBMET02567 | ||
| 0.292 | 0.004 | 0.292 | Dopamine D5 antagonist | 0.179 0.005 DBMET02565 0.176 0.005 DBMET02566 0.243 0.004 DBMET02567 | ||
| 0.289 | 0.003 | 0.317 | Histamine N-methyltransferase inhibitor | 0.317 0.003 DBMET02565 0.161 0.011 DBMET02566 0.232 0.004 DBMET02567 | DBMET02565 | |
| 0.291 | 0.006 | 0.291 | Nav1.6 sodium channel blocker | 0.266 0.008 DBMET02565 0.158 0.045 DBMET02566 0.249 0.01 DBMET02567 | ||
| 0.291 | 0.009 | 0.291 | Nav1.1 sodium channel blocker | 0.257 0.011 DBMET02565 0.17 0.026 DBMET02566 0.271 0.01 DBMET02567 | ||
| 0.282 | 0.006 | 0.304 | Protein kinase C zeta inhibitor | 0.266 0.006 DBMET02565 0.179 0.014 DBMET02566 0.304 0.005 DBMET02567 | DBMET02567 | |
| 0.282 | 0.012 | 0.282 | Butyrylcholinesterase inhibitor | 0.233 0.017 DBMET02565 0.103 0.059 DBMET02566 0.215 0.019 DBMET02567 | ||
| 0.285 | 0.017 | 0.387 | Antipruritic | 0.242 0.027 DBMET02565 0.387 0.007 DBMET02566 0.234 0.03 DBMET02567 | DBMET02566 | |
| 0.298 | 0.037 | 0.298 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.263 0.047 DBMET02565 0.212 0.068 DBMET02567 | ||
| 0.277 | 0.016 | 0.349 | Toll-Like receptor 9 antagonist | 0.22 0.028 DBMET02565 0.349 0.007 DBMET02566 0.223 0.027 DBMET02567 | DBMET02566 | |
| 0.266 | 0.008 | 0.289 | 5 Hydroxytryptamine uptake inhibitor | 0.289 0.006 DBMET02565 0.158 0.015 DBMET02566 0.136 0.018 DBMET02567 | DBMET02565 | |
| 0.297 | 0.047 | 0.297 | 5 Hydroxytryptamine uptake stimulant | 0.288 0.052 DBMET02565 0.239 0.093 DBMET02566 0.263 0.069 DBMET02567 | ||
| 0.254 | 0.005 | 0.254 | Dopamine D4 agonist | 0.194 0.007 DBMET02565 0.101 0.014 DBMET02566 0.109 0.013 DBMET02567 | ||
| 0.26 | 0.013 | 0.26 | Acetylcholine muscarinic antagonist | 0.204 0.023 DBMET02565 0.182 0.029 DBMET02566 0.216 0.021 DBMET02567 | ||
| 0.283 | 0.037 | 0.283 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.23 0.051 DBMET02565 0.19 0.068 DBMET02567 | ||
| 0.247 | 0.005 | 0.247 | 5 Hydroxytryptamine 3 antagonist | 0.201 0.005 DBMET02565 0.082 0.023 DBMET02566 0.077 0.025 DBMET02567 | ||
| 0.245 | 0.005 | 0.245 | Sphingomyelinase inhibitor | 0.181 0.014 DBMET02565 0.145 0.026 DBMET02566 0.205 0.009 DBMET02567 | ||
| 0.24 | 0.004 | 0.24 | Acetylcholine M5 receptor antagonist | 0.168 0.006 DBMET02565 0.131 0.01 DBMET02566 0.17 0.006 DBMET02567 | ||
| 0.33 | 0.097 | 0.33 | Calpain 2 inhibitor | 0.301 0.114 DBMET02565 0.213 0.176 DBMET02567 | ||
| 0.249 | 0.021 | 0.249 | Cholinergic antagonist | 0.209 0.03 DBMET02565 0.153 0.051 DBMET02566 0.195 0.033 DBMET02567 | ||
| 0.241 | 0.019 | 0.241 | Calcium channel blocker | 0.233 0.02 DBMET02565 0.222 0.023 DBMET02566 0.151 0.057 DBMET02567 | ||
| 0.222 | 0.002 | 0.222 | Ca2+-transporting ATPase inhibitor | 0.194 0.004 DBMET02565 0.185 0.005 DBMET02566 0.214 0.003 DBMET02567 | ||
| 0.235 | 0.023 | 0.235 | Acetylcholine antagonist | 0.196 0.032 DBMET02565 0.146 0.052 DBMET02566 0.182 0.036 DBMET02567 | ||
| 0.216 | 0.011 | 0.226 | 5 Hydroxytryptamine 3A agonist | 0.226 0.009 DBMET02565 0.161 0.03 DBMET02566 0.175 0.023 DBMET02567 | DBMET02565 | |
| 0.288 | 0.085 | 0.352 | Caspase 3 stimulant | 0.289 0.084 DBMET02565 0.352 0.058 DBMET02567 | DBMET02567 | |
| 0.204 | 0.013 | 0.204 | Protein kinase C gamma inhibitor | 0.196 0.015 DBMET02565 0.155 0.029 DBMET02566 0.186 0.017 DBMET02567 | ||
| 0.192 | 0.004 | 0.192 | 5 Hydroxytryptamine 3 agonist | 0.173 0.004 DBMET02565 0.103 0.014 DBMET02566 0.13 0.007 DBMET02567 | ||
| 0.246 | 0.062 | 0.266 | MAP-kinase-activated kinase 5 inhibitor | 0.266 0.05 DBMET02565 0.17 0.148 DBMET02566 0.219 0.083 DBMET02567 | DBMET02565 | |
| 0.238 | 0.056 | 0.238 | Anesthetic general | 0.151 0.112 DBMET02565 0.217 0.066 DBMET02567 | ||
| 0.21 | 0.03 | 0.21 | ATPase inhibitor | 0.185 0.052 DBMET02565 0.159 0.086 DBMET02566 0.195 0.042 DBMET02567 | ||
| 0.194 | 0.016 | 0.382 | Mediator release inhibitor | 0.164 0.023 DBMET02565 0.382 0.005 DBMET02566 0.299 0.007 DBMET02567 | DBMET02566 | |
| 0.183 | 0.007 | 0.214 | Alpha 1 adrenoreceptor agonist | 0.214 0.006 DBMET02565 0.119 0.013 DBMET02566 0.11 0.014 DBMET02567 | DBMET02565 | |
| 0.216 | 0.041 | 0.225 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.225 0.039 DBMET02565 0.117 0.086 DBMET02567 | DBMET02565 | |
| 0.303 | 0.13 | 0.416 | 15-Lipoxygenase inhibitor | 0.229 0.183 DBMET02565 0.416 0.068 DBMET02567 | DBMET02567 | |
| 0.177 | 0.004 | 0.177 | 5 Hydroxytryptamine 6 antagonist | 0.176 0.004 DBMET02565 0.129 0.009 DBMET02566 0.092 0.017 DBMET02567 | ||
| 0.195 | 0.026 | 0.197 | Adenylate cyclase inhibitor | 0.161 0.038 DBMET02565 0.197 0.026 DBMET02567 | DBMET02567 | |
| 0.305 | 0.138 | 0.305 | Analgesic | 0.257 0.176 DBMET02565 0.256 0.177 DBMET02567 | ||
| 0.177 | 0.011 | 0.247 | Alpha adrenoreceptor agonist | 0.247 0.006 DBMET02565 0.102 0.027 DBMET02566 0.122 0.021 DBMET02567 | DBMET02565 | |
| 0.171 | 0.006 | 0.179 | Glutamate release inhibitor | 0.109 0.032 DBMET02565 0.097 0.047 DBMET02566 0.179 0.005 DBMET02567 | DBMET02567 | |
| 0.171 | 0.008 | 0.178 | Adrenaline uptake inhibitor | 0.178 0.007 DBMET02565 0.118 0.014 DBMET02566 0.122 0.014 DBMET02567 | DBMET02565 | |
| 0.234 | 0.074 | 0.278 | Potassium channel blocker | 0.197 0.095 DBMET02565 0.278 0.054 DBMET02566 | DBMET02566 | |
| 0.165 | 0.008 | 0.172 | Lanosterol 14 alpha demethylase inhibitor | 0.172 0.006 DBMET02565 0.101 0.053 DBMET02566 0.146 0.013 DBMET02567 | DBMET02565 | |
| 0.161 | 0.005 | 0.161 | 5 Hydroxytryptamine 3A antagonist | 0.152 0.005 DBMET02565 0.09 0.023 DBMET02566 0.087 0.025 DBMET02567 | ||
| 0.2 | 0.044 | 0.2 | Diuretic | 0.163 0.067 DBMET02565 0.145 0.082 DBMET02566 0.177 0.056 DBMET02567 | ||
| 0.237 | 0.082 | 0.237 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.155 0.136 DBMET02565 0.212 0.093 DBMET02567 | ||
| 0.271 | 0.122 | 0.381 | Calcium channel activator | 0.381 0.033 DBMET02565 0.247 0.151 DBMET02566 0.276 0.117 DBMET02567 | DBMET02565 | |
| 0.239 | 0.092 | 0.239 | Gastrin inhibitor | 0.212 0.131 DBMET02566 | ||
| 0.167 | 0.02 | 0.171 | Heat shock protein 70 antagonist | 0.137 0.087 DBMET02565 0.134 0.102 DBMET02566 0.171 0.017 DBMET02567 | DBMET02567 | |
| 0.165 | 0.019 | 0.19 | Sphingosine 1-phosphate receptor 2 agonist | 0.19 0.013 DBMET02565 0.113 0.068 DBMET02566 0.141 0.031 DBMET02567 | DBMET02565 | |
| 0.177 | 0.033 | 0.185 | Neuropeptide Y1 antagonist | 0.185 0.026 DBMET02565 0.143 0.076 DBMET02566 0.167 0.043 DBMET02567 | DBMET02565 | |
| 0.202 | 0.062 | 0.217 | P-glycoprotein inhibitor | 0.168 0.092 DBMET02565 0.217 0.055 DBMET02566 0.193 0.069 DBMET02567 | DBMET02566 | |
| 0.2 | 0.062 | 0.213 | 5 Hydroxytryptamine 3E antagonist | 0.213 0.044 DBMET02565 0.186 0.089 DBMET02566 | DBMET02565 | |
| 0.159 | 0.023 | 0.159 | Acetylcholine agonist | 0.138 0.03 DBMET02565 0.075 0.074 DBMET02566 | ||
| 0.17 | 0.035 | 0.178 | MAP3K9 inhibitor | 0.178 0.028 DBMET02565 0.141 0.075 DBMET02566 0.157 0.049 DBMET02567 | DBMET02565 | |
| 0.142 | 0.008 | 0.145 | 5 Hydroxytryptamine 5A antagonist | 0.145 0.008 DBMET02565 0.074 0.028 DBMET02566 0.085 0.021 DBMET02567 | DBMET02565 | |
| 0.154 | 0.021 | 0.323 | 5 Hydroxytryptamine agonist | 0.323 0.007 DBMET02565 0.082 0.041 DBMET02566 | DBMET02565 | |
| 0.141 | 0.009 | 0.141 | 5 Hydroxytryptamine 5 antagonist | 0.141 0.009 DBMET02565 0.065 0.031 DBMET02566 0.075 0.023 DBMET02567 | ||
| 0.185 | 0.054 | 0.185 | Cholinergic | 0.146 0.08 DBMET02565 0.175 0.059 DBMET02567 | ||
| 0.134 | 0.004 | 0.134 | 5 Hydroxytryptamine 4 antagonist | 0.113 0.005 DBMET02565 0.105 0.005 DBMET02566 0.093 0.008 DBMET02567 | ||
| 0.242 | 0.113 | 0.242 | Ca(v)3.3 blocker | 0.22 0.152 DBMET02565 | ||
| 0.156 | 0.027 | 0.159 | DNA repair enzyme inhibitor | 0.143 0.038 DBMET02565 0.159 0.024 DBMET02567 | DBMET02567 | |
| 0.139 | 0.013 | 0.139 | Histamine H2 receptor antagonist | 0.125 0.018 DBMET02565 0.093 0.042 DBMET02566 0.094 0.041 DBMET02567 | ||
| 0.138 | 0.012 | 0.138 | Sigma receptor antagonist | 0.115 0.014 DBMET02565 0.084 0.019 DBMET02566 0.077 0.021 DBMET02567 | ||
| 0.129 | 0.005 | 0.133 | Protein kinase C beta inhibitor | 0.133 0.005 DBMET02565 0.089 0.02 DBMET02566 0.116 0.008 DBMET02567 | DBMET02565 | |
| 0.155 | 0.031 | 0.155 | Calcium channel (voltage-sensitive) blocker | 0.14 0.04 DBMET02565 0.124 0.052 DBMET02566 | ||
| 0.137 | 0.017 | 0.137 | Dopamine agonist | 0.12 0.02 DBMET02565 0.079 0.038 DBMET02566 0.134 0.017 DBMET02567 | ||
| 0.222 | 0.105 | 0.254 | 5 Hydroxytryptamine release stimulant | 0.254 0.087 DBMET02565 0.24 0.094 DBMET02566 0.189 0.131 DBMET02567 | DBMET02565 | |
| 0.137 | 0.023 | 0.214 | Telomerase inhibitor | 0.115 0.028 DBMET02565 0.214 0.013 DBMET02566 0.102 0.033 DBMET02567 | DBMET02566 | |
| 0.156 | 0.043 | 0.156 | Pregnane X receptor agonist | 0.134 0.089 DBMET02565 0.155 0.045 DBMET02566 0.138 0.079 DBMET02567 | ||
| 0.23 | 0.119 | 0.289 | Hypoxia-inducible factor 1 alpha inhibitor | 0.22 0.129 DBMET02565 0.289 0.071 DBMET02567 | DBMET02567 | |
| 0.126 | 0.015 | 0.126 | Acetylcholine M2 receptor antagonist | 0.079 0.03 DBMET02565 0.083 0.028 DBMET02566 0.085 0.026 DBMET02567 | ||
| 0.123 | 0.016 | 0.123 | 5 Hydroxytryptamine 1D antagonist | 0.104 0.021 DBMET02565 0.069 0.039 DBMET02566 0.055 0.054 DBMET02567 | ||
| 0.122 | 0.015 | 0.128 | Calcium channel L-type blocker | 0.128 0.014 DBMET02565 0.084 0.035 DBMET02566 0.075 0.045 DBMET02567 | DBMET02565 | |
| 0.111 | 0.004 | 0.111 | Adenylate cyclase 1 inhibitor | 0.096 0.005 DBMET02565 0.058 0.019 DBMET02566 0.099 0.004 DBMET02567 | ||
| 0.114 | 0.009 | 0.114 | Vanilloid 4 agonist | 0.087 0.03 DBMET02565 0.094 0.022 DBMET02566 0.084 0.034 DBMET02567 | ||
| 0.134 | 0.03 | 0.134 | Acetylcholine release stimulant | 0.113 0.061 DBMET02565 0.108 0.071 DBMET02566 | ||
| 0.13 | 0.027 | 0.13 | Acetylcholine nicotinic antagonist | 0.13 0.027 DBMET02565 0.088 0.048 DBMET02567 | ||
| 0.219 | 0.117 | 0.242 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.242 0.076 DBMET02565 | DBMET02565 | |
| 0.141 | 0.04 | 0.145 | Interleukin 8 antagonist | 0.145 0.037 DBMET02565 0.113 0.071 DBMET02566 0.133 0.047 DBMET02567 | DBMET02565 | |
| 0.113 | 0.014 | 0.163 | 5 Hydroxytryptamine 1A agonist | 0.163 0.01 DBMET02565 0.061 0.024 DBMET02566 0.049 0.029 DBMET02567 | DBMET02565 | |
| 0.129 | 0.03 | 0.129 | Calcium antagonist | 0.123 0.033 DBMET02565 | ||
| 0.187 | 0.09 | 0.22 | Neurotrophic factor enhancer | 0.164 0.118 DBMET02565 0.22 0.059 DBMET02567 | DBMET02567 | |
| 0.193 | 0.097 | 0.193 | ErbB-1 antagonist | 0.179 0.118 DBMET02566 0.186 0.106 DBMET02567 | ||
| 0.105 | 0.01 | 0.105 | Dopamine transporter inhibitor | 0.085 0.015 DBMET02565 0.077 0.018 DBMET02566 0.069 0.021 DBMET02567 | ||
| 0.129 | 0.036 | 0.181 | Protein kinase C mu inhibitor | 0.181 0.015 DBMET02565 0.097 0.06 DBMET02567 | DBMET02565 | |
| 0.111 | 0.019 | 0.111 | 5 Hydroxytryptamine 1 agonist | 0.102 0.02 DBMET02565 0.055 0.035 DBMET02566 | ||
| 0.097 | 0.005 | 0.097 | 5 Hydroxytryptamine 3B antagonist | 0.073 0.008 DBMET02565 0.048 0.015 DBMET02566 0.036 0.025 DBMET02567 | ||
| 0.127 | 0.038 | 0.127 | Insulin receptor antagonist | 0.096 0.067 DBMET02565 0.088 0.081 DBMET02567 | ||
| 0.104 | 0.016 | 0.104 | Acetylcholine muscarinic agonist | 0.065 0.03 DBMET02565 0.057 0.036 DBMET02566 | ||
| 0.101 | 0.017 | 0.101 | Protein kinase C eta inhibitor | 0.088 0.02 DBMET02565 0.068 0.029 DBMET02566 0.092 0.019 DBMET02567 | ||
| 0.112 | 0.029 | 0.112 | Bromodomain-containing protein 2 inhibitor | 0.086 0.064 DBMET02565 0.085 0.065 DBMET02566 | ||
| 0.132 | 0.05 | 0.132 | Calcium channel N-type blocker | 0.111 0.076 DBMET02565 0.124 0.058 DBMET02566 | ||
| 0.128 | 0.046 | 0.128 | Transcription factor STAT6 inhibitor | 0.126 0.05 DBMET02565 0.123 0.055 DBMET02567 | ||
| 0.173 | 0.093 | 0.189 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.189 0.082 DBMET02565 | DBMET02565 | |
| 0.177 | 0.098 | 0.177 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.172 0.103 DBMET02565 0.159 0.119 DBMET02567 | ||
| 0.167 | 0.089 | 0.174 | DNA methyltransferase I inhibitor | 0.174 0.084 DBMET02567 | DBMET02567 | |
| 0.091 | 0.014 | 0.091 | Acetylcholine M1 receptor agonist | 0.052 0.025 DBMET02565 0.045 0.029 DBMET02566 | ||
| 0.112 | 0.035 | 0.112 | Polo-like kinase-1 inhibitor | 0.083 0.077 DBMET02565 0.099 0.047 DBMET02567 | ||
| 0.083 | 0.008 | 0.083 | Histamine H4 receptor antagonist | 0.079 0.009 DBMET02565 0.052 0.027 DBMET02566 0.045 0.041 DBMET02567 | ||
| 0.102 | 0.027 | 0.102 | Caspase 7 inhibitor | 0.091 0.04 DBMET02565 0.076 0.072 DBMET02567 | ||
| 0.124 | 0.053 | 0.124 | Photosensitizer | 0.109 0.073 DBMET02565 0.114 0.065 DBMET02567 | ||
| 0.136 | 0.066 | 0.194 | Toll-Like receptor antagonist | 0.121 0.083 DBMET02565 0.194 0.033 DBMET02566 0.129 0.073 DBMET02567 | DBMET02566 | |
| 0.104 | 0.034 | 0.131 | Acetylcholine nicotinic agonist | 0.131 0.023 DBMET02565 | DBMET02565 | |
| 0.202 | 0.132 | 0.236 | Tyrosine 3 hydroxylase inhibitor | 0.192 0.151 DBMET02565 0.185 0.165 DBMET02566 0.236 0.082 DBMET02567 | DBMET02567 | |
| 0.144 | 0.074 | 0.172 | Adenylate cyclase stimulant | 0.172 0.033 DBMET02565 0.155 0.055 DBMET02567 | DBMET02565 | |
| 0.157 | 0.09 | 0.203 | 3C-like protease (Human coronavirus) inhibitor | 0.203 0.05 DBMET02565 | DBMET02565 | |
| 0.089 | 0.022 | 0.089 | Acetylcholine M3 receptor antagonist | 0.077 0.028 DBMET02565 0.086 0.023 DBMET02567 | ||
| 0.073 | 0.007 | 0.073 | Acetylcholine M4 receptor agonist | 0.048 0.012 DBMET02565 | ||
| 0.21 | 0.145 | 0.347 | Thyroid hormone beta antagonist | 0.194 0.16 DBMET02565 0.347 0.07 DBMET02566 0.187 0.166 DBMET02567 | DBMET02566 | |
| 0.08 | 0.019 | 0.122 | CC chemokine 2 receptor antagonist | 0.122 0.009 DBMET02565 0.061 0.032 DBMET02566 0.049 0.047 DBMET02567 | DBMET02565 | |
| 0.08 | 0.02 | 0.084 | MDM2 inhibitor | 0.084 0.016 DBMET02565 0.071 0.035 DBMET02566 | DBMET02565 | |
| 0.076 | 0.016 | 0.127 | 5 Hydroxytryptamine 2 agonist | 0.127 0.006 DBMET02565 0.052 0.035 DBMET02566 | DBMET02565 | |
| 0.076 | 0.02 | 0.076 | Nicotinic alpha7 receptor agonist | 0.067 0.025 DBMET02565 | ||
| 0.058 | 0.005 | 0.058 | ATM kinase inhibitor | 0.049 0.009 DBMET02565 0.046 0.01 DBMET02567 | ||
| 0.057 | 0.008 | 0.057 | Sigma 2 receptor antagonist | 0.038 0.013 DBMET02565 0.045 0.011 DBMET02566 0.037 0.014 DBMET02567 | ||
| 0.089 | 0.041 | 0.103 | Nicotinic alpha4beta2 receptor antagonist | 0.103 0.029 DBMET02565 | DBMET02565 | |
| 0.123 | 0.075 | 0.143 | Acetylcholinesterase inhibitor | 0.143 0.06 DBMET02567 | DBMET02567 | |
| 0.158 | 0.11 | 0.158 | DNA methylase inhibitor | 0.156 0.112 DBMET02567 | ||
| 0.112 | 0.065 | 0.14 | MAP kinase 13 inhibitor | 0.14 0.041 DBMET02565 0.096 0.089 DBMET02566 | DBMET02565 | |
| 0.205 | 0.158 | 0.341 | Thyroid hormone antagonist | 0.187 0.173 DBMET02565 0.341 0.076 DBMET02566 0.187 0.173 DBMET02567 | DBMET02566 | |
| 0.059 | 0.014 | 0.065 | Benzodiazepine antagonist | 0.05 0.027 DBMET02565 0.065 0.01 DBMET02566 | DBMET02566 | |
| 0.167 | 0.122 | 0.167 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.157 0.134 DBMET02565 | ||
| 0.056 | 0.011 | 0.056 | p53 inhibitor | 0.055 0.011 DBMET02565 0.048 0.015 DBMET02566 0.036 0.024 DBMET02567 | ||
| 0.101 | 0.058 | 0.117 | Nitric-oxide synthase inhibitor | 0.117 0.04 DBMET02565 | DBMET02565 | |
| 0.067 | 0.025 | 0.067 | Melanin-concentrating hormone receptor 1 antagonist | 0.047 0.044 DBMET02565 | ||
| 0.078 | 0.036 | 0.078 | Acetylcholine M5 receptor agonist | 0.064 0.051 DBMET02565 | ||
| 0.07 | 0.028 | 0.088 | Nicotinic neuronal receptor agonist | 0.088 0.017 DBMET02565 | DBMET02565 | |
| 0.078 | 0.038 | 0.122 | Phospholipase D inhibitor | 0.122 0.006 DBMET02565 | DBMET02565 | |
| 0.05 | 0.01 | 0.05 | Sigma 1 receptor antagonist | 0.041 0.012 DBMET02565 0.042 0.012 DBMET02566 0.025 0.02 DBMET02567 | ||
| 0.12 | 0.081 | 0.12 | Antibacterial (Helicobacter pylori) | 0.117 0.086 DBMET02565 | ||
| 0.055 | 0.016 | 0.061 | Dopamine D3 agonist | 0.061 0.014 DBMET02565 0.036 0.031 DBMET02566 0.045 0.022 DBMET02567 | DBMET02565 | |
| 0.106 | 0.068 | 0.117 | DNA intercalator | 0.095 0.078 DBMET02565 0.117 0.059 DBMET02567 | DBMET02567 | |
| 0.064 | 0.026 | 0.065 | 5 Hydroxytryptamine 7 agonist | 0.065 0.024 DBMET02565 0.053 0.045 DBMET02567 | DBMET02565 | |
| 0.041 | 0.005 | 0.041 | Myristoyl transferase inhibitor | 0.039 0.006 DBMET02565 | ||
| 0.062 | 0.026 | 0.062 | Lysine-specific demethylase 1A inhibitor | 0.057 0.032 DBMET02565 | ||
| 0.047 | 0.012 | 0.047 | Potassium channel small-conductance Ca-activated activator | 0.038 0.016 DBMET02565 | ||
| 0.048 | 0.016 | 0.048 | Heme oxygenase inhibitor | 0.046 0.02 DBMET02565 | ||
| 0.096 | 0.064 | 0.096 | Electrolyte absorption antagonist | 0.086 0.081 DBMET02565 | ||
| 0.05 | 0.018 | 0.05 | Nerve growth factor antagonist | 0.039 0.038 DBMET02565 | ||
| 0.173 | 0.142 | 0.223 | DNA damaging | 0.164 0.153 DBMET02565 0.223 0.098 DBMET02566 | DBMET02566 | |
| 0.06 | 0.029 | 0.081 | Myc inhibitor | 0.081 0.013 DBMET02565 | DBMET02565 | |
| 0.175 | 0.145 | 0.21 | Cardiotonic | 0.21 0.109 DBMET02566 | DBMET02566 | |
| 0.256 | 0.226 | 0.256 | MAP kinase 1 inhibitor | |||
| 0.059 | 0.03 | 0.11 | NMDA 2A receptor antagonist | 0.11 0.011 DBMET02565 0.07 0.024 DBMET02567 | DBMET02565 | |
| 0.096 | 0.067 | 0.177 | MAO A inhibitor | 0.089 0.072 DBMET02566 0.177 0.034 DBMET02567 | DBMET02567 | |
| 0.054 | 0.024 | 0.06 | Dopamine D2 agonist | 0.05 0.027 DBMET02565 0.043 0.032 DBMET02566 0.06 0.021 DBMET02567 | DBMET02567 | |
| 0.13 | 0.101 | 0.162 | Sphingosine 1-phosphate receptor 5 antagonist | 0.134 0.091 DBMET02565 0.162 0.043 DBMET02566 0.132 0.095 DBMET02567 | DBMET02566 | |
| 0.041 | 0.013 | 0.044 | Endothelial nitric-oxide synthase inhibitor | 0.044 0.011 DBMET02565 | DBMET02565 | |
| 0.102 | 0.074 | 0.12 | GABA receptor agonist | 0.12 0.057 DBMET02566 | DBMET02566 | |
| 0.094 | 0.067 | 0.147 | Creatine kinase inhibitor | 0.147 0.025 DBMET02567 | DBMET02567 | |
| 0.065 | 0.038 | 0.102 | NMDA 2C receptor antagonist | 0.102 0.015 DBMET02565 0.067 0.037 DBMET02567 | DBMET02565 | |
| 0.063 | 0.037 | 0.081 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.057 0.051 DBMET02565 0.081 0.018 DBMET02567 | DBMET02567 | |
| 0.042 | 0.019 | 0.042 | Delayed rectifier potassium channel blocker | 0.037 0.027 DBMET02566 | ||
| 0.144 | 0.121 | 0.177 | Catenin beta inhibitor | 0.162 0.08 DBMET02565 0.177 0.056 DBMET02567 | DBMET02567 | |
| 0.062 | 0.039 | 0.063 | Cyclin D1 inhibitor | 0.063 0.038 DBMET02565 | DBMET02565 | |
| 0.074 | 0.052 | 0.074 | Potassium channel (Tandem pore domain) blocker | 0.071 0.059 DBMET02565 | ||
| 0.198 | 0.178 | 0.224 | Vasodilator, peripheral | 0.224 0.15 DBMET02565 0.212 0.162 DBMET02566 0.214 0.161 DBMET02567 | DBMET02565 | |
| 0.068 | 0.047 | 0.088 | Protein kinase C alpha inhibitor | 0.088 0.028 DBMET02565 | DBMET02565 | |
| 0.033 | 0.013 | 0.033 | 5 Hydroxytryptamine 6 agonist | 0.033 0.012 DBMET02565 | ||
| 0.082 | 0.063 | 0.156 | NMDA receptor antagonist | 0.138 0.028 DBMET02565 0.156 0.023 DBMET02566 0.123 0.034 DBMET02567 | DBMET02566 | |
| 0.104 | 0.086 | 0.177 | MAO inhibitor | 0.177 0.049 DBMET02567 | DBMET02567 | |
| 0.038 | 0.02 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.034 0.029 DBMET02567 | ||
| 0.08 | 0.064 | 0.081 | CC chemokine 5 receptor agonist | 0.081 0.06 DBMET02565 0.081 0.06 DBMET02567 | DBMET02567 | |
| 0.034 | 0.019 | 0.034 | Vanilloid 4 antagonist | 0.03 0.028 DBMET02565 | ||
| 0.084 | 0.071 | 0.102 | Potassium channel (Ca-activated) activator | 0.102 0.054 DBMET02567 | DBMET02567 | |
| 0.189 | 0.175 | 0.281 | Cholesterol antagonist | 0.281 0.104 DBMET02567 | DBMET02567 | |
| 0.035 | 0.022 | 0.058 | Benzodiazepine receptor peripheral-type antagonist | 0.033 0.027 DBMET02565 0.058 0.005 DBMET02566 | DBMET02566 | |
| 0.052 | 0.039 | 0.054 | Protein kinase C epsilon inhibitor | 0.054 0.036 DBMET02565 | DBMET02565 | |
| 0.076 | 0.065 | 0.076 | Acetylcholine M3 receptor agonist | |||
| 0.045 | 0.035 | 0.05 | CC chemokine 4 receptor antagonist | 0.046 0.035 DBMET02565 0.05 0.028 DBMET02566 | DBMET02566 | |
| 0.089 | 0.079 | 0.089 | Phosphodiesterase 6D inhibitor | |||
| 0.057 | 0.049 | 0.057 | Potassium channel (Ca-activated) blocker | |||
| 0.038 | 0.03 | 0.044 | GABA uptake inhibitor | 0.044 0.021 DBMET02565 0.038 0.03 DBMET02566 | DBMET02565 | |
| 0.22 | 0.213 | 0.22 | DNA directed DNA polymerase inhibitor | 0.219 0.213 DBMET02567 | ||
| 0.032 | 0.027 | 0.032 | Protein kinase C beta I inhibitor | 0.032 0.027 DBMET02567 | ||
| 0.031 | 0.027 | 0.035 | Protein kinase C beta II inhibitor | 0.035 0.017 DBMET02565 0.031 0.027 DBMET02567 | DBMET02565 | |
| 0.074 | 0.07 | 0.101 | Neuropeptide Y antagonist | 0.101 0.04 DBMET02565 | DBMET02565 | |
| 0.041 | 0.038 | 0.042 | Histamine H1 receptor agonist | 0.042 0.034 DBMET02565 | DBMET02565 | |
| 0.039 | 0.036 | 0.071 | NMDA receptor subunit 3B antagonist | 0.053 0.023 DBMET02565 0.071 0.016 DBMET02567 | DBMET02567 | |
| 0.096 | 0.093 | 0.096 | c-Src kinase inhibitor | |||
| 0.13 | 0.127 | 0.175 | Tumour necrosis factor antagonist | 0.175 0.072 DBMET02565 | DBMET02565 | |
| 0.045 | 0.043 | 0.054 | CC chemokine receptor 2B antagonist | 0.054 0.025 DBMET02565 | DBMET02565 | |
| 0.041 | 0.039 | 0.041 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.063 | 0.063 | 0.064 | Benzodiazepine agonist | 0.064 0.061 DBMET02566 | DBMET02566 | |
| 0.043 | 0.044 | 0.059 | Potassium channel (Inward rectifier) blocker | 0.059 0.024 DBMET02566 | DBMET02566 | |
| 0.053 | 0.055 | 0.091 | 5 Hydroxytryptamine 2A agonist | 0.091 0.019 DBMET02565 | DBMET02565 | |
| 0.07 | 0.075 | 0.088 | Glycine receptor antagonist | 0.088 0.045 DBMET02565 | DBMET02565 | |
| 0.022 | 0.027 | 0.026 | Cyclin E2 inhibitor | 0.026 0.022 DBMET02565 | DBMET02565 | |
| 0.051 | 0.057 | 0.059 | Cannabinoid CB1 receptor antagonist | 0.059 0.046 DBMET02566 | DBMET02566 | |
| 0.121 | 0.127 | 0.145 | Dual specificity phosphatase 3 inhibitor | 0.145 0.1 DBMET02567 | DBMET02567 | |
| 0.05 | 0.059 | 0.07 | Cannabinoid receptor agonist | 0.07 0.041 DBMET02566 | DBMET02566 | |
| 0.079 | 0.089 | 0.123 | Chemokine receptor antagonist | 0.123 0.046 DBMET02565 0.098 0.065 DBMET02566 | DBMET02565 | |
| 0.095 | 0.106 | 0.12 | MAP kinase 12 inhibitor | 0.12 0.07 DBMET02565 | DBMET02565 | |
| 0.184 | 0.197 | 0.349 | Beta lactamase inhibitor | 0.349 0.116 DBMET02566 | DBMET02566 | |
| 0.142 | 0.158 | 0.233 | Antiamyloidogenic | 0.233 0.079 DBMET02567 | DBMET02567 | |
| 0.258 | 0.274 | 0.302 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.302 0.21 DBMET02565 | DBMET02565 | |
| 0.023 | 0.04 | 0.029 | Estrogen-related receptor gamma antagonist | 0.029 0.019 DBMET02567 | DBMET02567 | |
| 0.025 | 0.046 | 0.042 | NMDA receptor subunit 3A antagonist | 0.036 0.029 DBMET02565 0.042 0.024 DBMET02567 | DBMET02567 | |
| 0.04 | 0.065 | 0.075 | Cannabinoid CB1 receptor agonist | 0.075 0.032 DBMET02566 | DBMET02566 | |
| 0.047 | 0.077 | 0.063 | Lipase inhibitor | 0.063 0.061 DBMET02567 | DBMET02567 | |
| 0.078 | 0.109 | 0.111 | Alpha 2d adrenoreceptor antagonist | 0.111 0.033 DBMET02565 | DBMET02565 | |
| 0.08 | 0.111 | 0.132 | Beta glucuronidase inhibitor | 0.132 0.036 DBMET02565 0.1 0.069 DBMET02567 | DBMET02565 | |
| 0.144 | 0.18 | 0.213 | Streptokinase A inhibitor | 0.213 0.125 DBMET02567 | DBMET02567 | |
| 0.094 | 0.132 | 0.133 | CDC-like kinase 1 inhibitor | 0.133 0.083 DBMET02567 | DBMET02567 | |
| 0.051 | 0.088 | 0.07 | CXC chemokine receptor antagonist | 0.07 0.049 DBMET02565 | DBMET02565 | |
| 0.174 | 0.214 | 0.192 | Antithrombotic | 0.192 0.187 DBMET02565 | DBMET02565 | |
| 0.041 | 0.082 | 0.061 | Alpha 2 adrenoreceptor agonist | 0.061 0.041 DBMET02565 | DBMET02565 | |
| 0.023 | 0.065 | 0.039 | Estrogen-related receptor beta antagonist | 0.039 0.012 DBMET02567 | DBMET02567 | |
| 0.052 | 0.097 | 0.078 | CC chemokine receptor antagonist | 0.078 0.053 DBMET02565 0.076 0.056 DBMET02566 | DBMET02565 | |
| 0.05 | 0.095 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.055 DBMET02565 | DBMET02565 | |
| 0.063 | 0.109 | 0.098 | Protein kinase C delta inhibitor | 0.098 0.054 DBMET02565 | DBMET02565 | |
| 0.041 | 0.089 | 0.096 | NMDA 2 receptor antagonist | 0.096 0.034 DBMET02565 0.065 0.056 DBMET02567 | DBMET02565 | |
| 0.151 | 0.2 | 0.184 | Prostaglandin dehydrogenase inhibitor | 0.184 0.169 DBMET02567 | DBMET02567 | |
| 0.059 | 0.108 | 0.101 | Estrogen receptor alpha antagonist | 0.101 0.026 DBMET02567 | DBMET02567 | |
| 0.102 | 0.155 | 0.221 | Amyloid beta aggregation inhibitor | 0.221 0.068 DBMET02567 | DBMET02567 | |
| 0.027 | 0.081 | 0.051 | Phenylethanolamine N methyltransferase inhibitor | 0.051 0.014 DBMET02565 | DBMET02565 | |
| 0.09 | 0.143 | 0.112 | Protein kinase C nu inhibitor | 0.112 0.102 DBMET02565 | DBMET02565 | |
| 0.019 | 0.074 | 0.031 | Carnitine palmitoyltransferase 1 inhibitor | 0.031 0.029 DBMET02566 | DBMET02566 | |
| 0.047 | 0.102 | 0.059 | Interferon inducer | 0.059 0.055 DBMET02565 | DBMET02565 | |
| 0.054 | 0.112 | 0.071 | Interferon agonist | 0.071 0.068 DBMET02565 | DBMET02565 | |
| 0.022 | 0.081 | 0.042 | Dopamine D5 agonist | 0.042 0.026 DBMET02565 | DBMET02565 | |
| 0.016 | 0.077 | 0.029 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.029 0.026 DBMET02567 | DBMET02567 | |
| 0.106 | 0.167 | 0.127 | Dual specificity phosphatase inhibitor | 0.127 0.125 DBMET02567 | DBMET02567 | |
| 0.058 | 0.119 | 0.081 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.081 0.062 DBMET02567 | DBMET02567 | |
| 0.099 | 0.161 | 0.134 | Sphingosine 1-phosphate receptor 2 antagonist | 0.134 0.066 DBMET02566 | DBMET02566 | |
| 0.067 | 0.132 | 0.113 | Cystathionine beta-synthase inhibitor | 0.113 0.064 DBMET02567 | DBMET02567 | |
| 0.015 | 0.08 | 0.107 | 5 Hydroxytryptamine 2C agonist | 0.107 0.007 DBMET02565 | DBMET02565 | |
| 0.139 | 0.207 | 0.226 | Superoxide dismutase inhibitor | 0.226 0.092 DBMET02565 | DBMET02565 | |
| 0.029 | 0.098 | 0.049 | Carnitine palmitoyltransferase 1B inhibitor | 0.049 0.03 DBMET02566 | DBMET02566 | |
| 0.013 | 0.083 | 0.054 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.054 0.014 DBMET02567 | DBMET02567 | |
| 0.047 | 0.119 | 0.08 | MAO B inhibitor | 0.08 0.075 DBMET02567 | DBMET02567 | |
| 0.017 | 0.09 | 0.051 | Estradiol 17 beta-dehydrogenase inhibitor | 0.051 0.024 DBMET02567 | DBMET02567 | |
| 0.125 | 0.198 | 0.164 | Vasodilator | 0.164 0.138 DBMET02567 | DBMET02567 | |
| 0.055 | 0.129 | 0.11 | Topoisomerase I inhibitor | 0.11 0.062 DBMET02567 | DBMET02567 | |
| 0.21 | 0.289 | 0.268 | 5 Hydroxytryptamine release inhibitor | 0.268 0.204 DBMET02565 | DBMET02565 | |
| 0.169 | 0.248 | 0.293 | Antiobesity | 0.293 0.121 DBMET02565 | DBMET02565 | |
| 0.033 | 0.118 | 0.056 | Protein kinase C iota inhibitor | 0.056 0.044 DBMET02565 | DBMET02565 | |
| 0.059 | 0.146 | 0.12 | Topoisomerase II inhibitor | 0.12 0.067 DBMET02567 | DBMET02567 | |
| 0.035 | 0.128 | 0.053 | Glucosylceramidase inhibitor | 0.053 0.042 DBMET02565 | DBMET02565 | |
| 0.028 | 0.127 | 0.057 | Alpha 1L adrenoreceptor agonist | 0.057 0.01 DBMET02565 | DBMET02565 | |
| 0.023 | 0.121 | 0.041 | 5 Hydroxytryptamine 2B agonist | 0.041 0.023 DBMET02565 | DBMET02565 | |
| 0.043 | 0.151 | 0.074 | Adrenaline agonist | 0.074 0.067 DBMET02565 | DBMET02565 | |
| 0.132 | 0.249 | 0.187 | Transcription factor NF kappa B inhibitor | 0.187 0.182 DBMET02567 | DBMET02567 | |
| 0.056 | 0.173 | 0.17 | Estrogen receptor beta antagonist | 0.17 0.013 DBMET02567 | DBMET02567 | |
| 0.02 | 0.141 | 0.051 | CC chemokine 5 receptor antagonist | 0.051 0.035 DBMET02566 | DBMET02566 | |
| 0.085 | 0.21 | 0.168 | NOS3 expression enhancer | 0.168 0.057 DBMET02567 | DBMET02567 | |
| 0.066 | 0.201 | 0.184 | Estrogen antagonist | 0.184 0.015 DBMET02567 | DBMET02567 | |
| 0.027 | 0.163 | 0.119 | Leukotriene synthesis inhibitor | 0.119 0.017 DBMET02566 | DBMET02566 | |
| 0.138 | 0.278 | 0.227 | Alpha-glucosidase inhibitor | 0.227 0.201 DBMET02567 | DBMET02567 | |
| 0.008 | 0.151 | 0.03 | Carnitine palmitoyltransferase 1A inhibitor | 0.03 0.017 DBMET02566 | DBMET02566 | |
| 0.023 | 0.169 | 0.045 | Purinergic P2X4 antagonist | 0.045 0.033 DBMET02565 | DBMET02565 | |
| 0.004 | 0.152 | 0.054 | Estrogen receptor alpha agonist | 0.054 0.016 DBMET02567 | DBMET02567 | |
| 0.083 | 0.234 | 0.168 | Dyrk kinase inhibitor | 0.168 0.12 DBMET02567 | DBMET02567 | |
| 0.075 | 0.237 | 0.17 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.17 0.114 DBMET02567 | DBMET02567 | |
| 0.052 | 0.222 | 0.122 | Lipid peroxidase inhibitor | 0.122 0.092 DBMET02567 | DBMET02567 | |
| 0.093 | 0.308 | 0.184 | Lipoxygenase inhibitor | 0.184 0.158 DBMET02567 | DBMET02567 | |
| 0.053 | 0.269 | 0.244 | Interleukin 1 antagonist | 0.244 0.02 DBMET02566 | DBMET02566 | |
| 0.027 | 0.247 | 0.047 | Alpha 1b adrenoreceptor agonist | 0.047 0.042 DBMET02565 | DBMET02565 | |
| 0.007 | 0.234 | 0.067 | Estrogen agonist | 0.067 0.027 DBMET02567 | DBMET02567 | |
| 0.005 | 0.318 | 0.062 | Beta tubulin antagonist | 0.062 0.039 DBMET02566 | DBMET02566 | |
| 0.044 | 0.404 | 0.168 | Free radical scavenger | 0.168 0.126 DBMET02567 | DBMET02567 | |
| 0.038 | 0.489 | 0.163 | Tumour necrosis factor alpha release inhibitor | 0.163 0.142 DBMET02566 | DBMET02566 | |
| 0.018 | 0.755 | 0.164 | Interleukin 1b antagonist | 0.164 0.031 DBMET02566 | DBMET02566 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |